Social Links

Follow on Facebook Follow on TwitterFollow EiR on PinterestFollow EiR on Instagram

Xpert Access


Login To Get Involved!

Forgot your username?

Forgot your password?


Join Us At EiR Now!

DNRS Roof Banner


DNRS 4th of July Sale! 15% Discount with Code:

Universal AJAX Live Search

Search - Categories
Search - Contacts
Search - Content
Search - Newsfeeds
Search - Weblinks

Profile of Patients with Chemical Injury and Sensitivity - References





  1. Osler W. The hospital and the college (address delivered in 1903 to the New York Academy of Medicine). In: The Collected Essays of William Osler (McGovern JP, Roland CG eds). Birmingham, AL:Classics of Medicine Library, 1985;2:239-254.
  2. Silbergeld EK, Fowler BA, eds. Mechanisms of chemical induced porphyrinopathies. Ann NY Acad Sci 514:1-350 (1987).
  3. Fowler BK, Oskarsson A, Woods JS. Metal- and metalloid-induced porphyrinurias: relationships to cell injury. Ann NY Acad Sci 514:172-182 (1987).
  4. Rimington C. Experimental porphyria in rats induced by chlorinated benzenes. Biochem Pharmacol 12:1387-1397 (1963).
  5. Bickers D, Miller L, Kappas A. Exacerbation of hereditary hepatic porphyria by surreptitious ingestion of an usual provocative agent--mouthwash. N Engl J Med 292:1115-1116 (1975).
  6. McConnachie P, Zahalsky AC. Immune alterations in humans exposed to the termiticide technical chlordane. Arch Env Health 47:295-301 (1992).
  7. Broughton A, Thrasher JD, Gard Z. Immunological evaluation of four arc welders exposed to fumes from ignited polyurethane (isocyanate) foam. Am J Ind Med 13:463-472 (1988).
  8. Denkhaus W, von Steldem D, Botzenhardt U, Konietzho H. Lymphocyte subpopulations in solvent-exposed workers. Int Arch Occup Environ Health 57:109-115 (1986).
  9. Byers V, Levin AS, Ozonoff DM, Baldwin RW. Association between clinical symptoms and lymphocyte abnormalities in a population with chronic domestic exposure to industrial solvent-contaminated water supply and a high incidence of leukemia. Cancer Immunol Immunother 27:77-81 (1988).
  10. Haustein UF, Ziegler V. Environmentally induced systemic sclerosis-like disorders. Int J Derm 24:147-151 (1985).
  11. Thrasher J, Broughton A, Madison R. Immune activation and autoantibodies in humans with long-term inhalation exposure to formaldehyde. Arch Environ Health 45:217-223 (1990).
  12. Madison R, Broughton A, Thrasher JD. Immunologic biomarkers associated with an acute exposure to exothermic byproducts of an urea formaldehyde spill. Environ Health Perspect 94:219-223 (1991).
  13. Editorial. Silicone implants and systemic immunologic disease. Toxicol Ind Health 8:231-237 (1992).
  14. Broughton A. Chronic health effects and immunologic alterations associated with exposure to pesticides. Comments Toxicol 4:59-71 (1990).
  15. Middaugh DA, Pinney SM, Linz DH. Sick building syndrome. J Occup Med 34:1197-1203 (1992).
  16. Daniell W, Couser WG, Rosenstock L. Occupational solvent exposure and glomerulonephritis. JAMA 259:2280-2283 (1988).
  17. Bombassei G, Kaplan AA. The association between hydrocarbon exposure and anti-glomerular basement membrane antibody-mediated disease (Goodpastures syndrome). Am J Ind Med 21:141-153 (1992).
  18. Safran M, Paul TL, Roti E, Braverman LE. Environmental factors affecting autoimmune thyroid disease. Endocrinol Metab Clin North Am 16:327-341 (1987).
  19. Street J. Pesticides and the immune system. In: Immunologic Considerations in Toxicology (Sharma R, ed). Boca Raton, FL:CRC Press, 1981;49.
  20. Press R, Peebles CL, Kumagai Y, Ochs RL, Tan EM. Antinuclear autoantibodies in women with silicone breast implants. Lancet 340:1304-1307 (1992).
  21. Thrasher JD, Madison R, Broughton A, Gard Z. Building-related illness and antibodies to albumin, conjugates of albumin, toluene, diisocyanates, and trimellitic anhydride. Am J Ind Med 15:187-195 (1989).
  22. Slade M, Simmons RL, Yunis E, Greenberg LJ. Immunodepression after major surgery in normal patients. Surgery 78:363-372 (1975).
  23. Tonneson E, Huttel MS, Christensen NJ, Schmitz O. Natural killer cell activity in patients undergoing upper abdominal surgery: relationship to the endocrine stress response. Acta Anaesthesiol Scand 28(6):654-660 (1984).
  24. Heuser G. Diagnostic markers in chemical immunotoxicology and neurotoxicology. J Occup Med Toxicol 1:v-x (1992).
  25. Matikainen E, Juntunen J. Autonomic nervous system dysfunction in workers. J Neurol Neurosurg Psychiatry 48:1021-1024 (1985).
  26. Morrow L, Ryan CM, Hodgson MJ, Robin N. Alterations in cognitive and psychological functioning after organic solvent exposure. J Occup Med 32:444-450 (1990).
  27. Morrow L, Ryan CM, Hodgson MJ, Robin N. Risk factors associated with persistence of neuropsychological deficits in persons with organic solvent exposure. J Nerv Ment Dis 179:540-545 (1991).
  28. Gyntelberg F, Vesterhauge S, Fog P, Isager H, Zillstorff K. Acquired intolerance to organic solvents and results of vestibular testing. Am J Ind Med 9:363-370 (1986).
  29. Morata T, Dunn DE, Sieber WK. Effects of occupational exposure to organic solvents and noise on hearing. Scand J Work Environ Health 19:245-254 (1993).
  30. Linz D, deGarmo P, Morton W, Weins A, Coull B, Maricle R. Organic solvent-induced encephalopathy in industrial painters. J Occup Med 28:119-125 (1986).
  31. Savage EP, Keefe TJ, Mounce LM, Lewis JA, Heaton RK, Burcar PJ. Chronic neurological sequelae of acute organophosphate pesticide poisoning. Arch Environ Health 43:38-45 (1988).
  32. Jusic A. Anticholinesterase pesticides of organophosphorus type: electromyographic, neurological and psychological studies in occupationally exposed workers. In: Behavioral Toxicology: Early Detection of Occupational Hazards (Xintras C, Johnson BL, deGrott I, eds). NIOSH 74-126. Washington:National Institute for Occupational Safety and Health, 1986;182-190.
  33. Troster A, Ruff R. Neuropsychological sequelae of exposure to the chlorinated hydrocarbon solvents trichloroethylene and trichloroethane. Arch Clin Neuropsy 5:31-47 (1990).
  34. Hartlage L, Johnson D, Burns T, Williams B. Neurotoxicological screening in community settings. Arch Clin Neuropsy 9:139-140 (1994).
  35. Doty R, Deems DA, Frye RE, Pelberg R, Shapiro A. Olfactory sensitivity, nasal resistance, and autonomic function in patients with multiple chemical sensitivity. Arch Otolaryngol Head Neck Surg 114:1422-1427 (1988).
  36. Ryan CM, Morrow LA, Hodgson M. Cacosmia and neurobehavioral dysfunction associated with occupational exposures to mixtures of organic solvents. Amer J Psychiatry 145:1442-1445 (1988).
  37. Rosenthal N, Cameron CL. Exaggerated sensitivity to an organophosphate pesticide. Am J Psychiatry 148:2 (1991).
  38. Cone J, Sult TA. Acquired intolerance to solvents following pesticide/solvent exposure in a building: a new group of workers at risk for multiple chemical sensitivities. Toxicol Ind Health 8:29-39 (1992).
  39. Broughton A. Antibodies and altered cell immunity in formaldehyde-exposed humans. Comments Toxicol 2:155-174 (1988).
  40. Davidoff A, Fogarty L. Psychogenic origins of multiple chemical sensitivities syndrome: a critical review of the research literature. Arch Environ Health 49:316-325 (1994).
  41. Callender T, Morrow L, Subramanian K, Duhon D, Ristovv M. Three-dimensional brain metabolic imaging in patients with toxic encephalopathy. Environ Res 60: 295-319 (1993).
  42. Heuser G, Wodjani A, Heuser S. Diagnostic markers in chemical sensitivity. In: Multiple Chemical Sensitivities: Addendum to Biologic Markers in Immunotoxicology. Washington:
    National Academy Press, 1992;117-138.
  43. Fiedler N, Maccia C, Kipen H. Evaluation of chemically-sensitive patients. J Occup Med 34:529-538 (1992).
  44. Meggs W, Cleveland C. Rhinolaryngoscopic examination of patients with multiple chemical sensitivity syndrome. Arch Environ Health 48(1):14-18 (1993).
  45. Buchwald D, Garrity D. Comparison of patients with chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivities. Arch Int Med 154:2049-2053 (1994).
  46. Romano T, Stiller J. Abnormal cutaneous perception in primary, secondary and post-traumatic fibromyalgia patients. Arthritis Rheum 31(Suppl 4):S99 (1988).
  47. Russell IJ, Vipraio GA, Michalek J, Fletcher E. Abnormal T cell subpopulations in fibrositis syndrome. Arthritis and Rheum 31(Suppl 4):S99 (1988).
  48. Goldenberg D, Simms RW, Geiger A, Komaroff A. High frequency of fibromyalgia in patients with chronic fatigue seen in a primary care practice. Arthritis Rheum 33:381-387 (1990).
  49. Klimas N, Salvato FR, Morgan R, Fletcher MA. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol 28:1403-1410 (1990).
  50. Cotton P. Treatment proposed for chronic fatigue syndrome; research continues to compile data on disorder. JAMA 266:2667-2668 (1991).
  51. Cheney P. Proposed pathophysiologic mechanism of CFIDS. CFIDS Chronicle, Spring 1994;1-3.
  52. Bell IR. White paper: neuropsychiatric aspects of sensitivity to low-level chemicals: a neural sensitization model. Toxicol Ind Health 10:277-312 (1994).
  53. Goldstein J. The evolving hypothesis. CFS: Limbic encephalopathy in a dysfunctional neuroimmune network. CFIDS Chronicle, Fall 1991;19-24.
  54. Davidoff L. Symptoms and health status in individuals with multiple chemical sensitivities syndrome from four reported sensitizing exposures and a general population comparison group. Arch Environ Health 51:201-213 (1996).
  55. Hafler D, Fox DA, Benjamin D, Weiner HL. Antigen reactive memory T cells are defined by TA1. J Immunol 137:414-418 (1986).
  56. Simon G. Question and answer session 3. In: Proceedings of the Conference on Low-Level Exposure to Chemicals and Neurobiologic Sensitivity, 6-7 April 1994, Baltimore, Maryland (Mitchell FL, ed). J Toxicol Ind Health 10:526-527 (1994).
  57. Baker GP. Porphyria and MCS symptoms overlap--another chemical connection. Townsend Letter for Doctors 144:72-73 (1995).
  58. Donnay A, Ziem G. Protocol for Diagnosing Disorders of Porphyrin Metabolism in Chemically-Sensitive Patients. Baltimore, MD:MCS Referral & Resources, Inc., 1995.
  59. Kappas A, Sassa S, Galbraith RA, Norman Y. The porphyrias. In: The Metabolic Basis of Inherited Disease, 6th ed. (Scriver CR, Beaudet AL, Sly WS, Valle D, eds). New York:McGraw-Hill Information Services Company, 1989;1305-1365.
  60. Simon G, Daniell W, Stockbridge H, Claypoole K, Rosenstock L. Immunologic, psychological and neuropsychological factors in multiple chemical sensitivity: a controlled study. Ann Intern Med 119: 97-103 (1993).
  61. Ziem G, Donnay A. Chronic fatigue, fibromyalgia and chemical sensitivity: overlapping disorders. Arch Intern Med 155:1913 (1995).
  62. Davidoff R. Migraines: Manifestations, Pathogenesis and Management. Philadelphia:FA Davis, 1995.
  63. Hagstadius S, Orbaek P, Risberg J, Lindgren M. Regional cerebral blood flow at the time of diagnosis of chronic toxic encephalopathy induced by organic solvent exposure and after cessation of exposure. Scand J Work Environ Health 15:130-135 (1989).
  64. Callender T, Morrow L, Subramanian K, Duhon D, Ristovv M. Three-dimensional brain metabolic imaging in patients with toxic encephalopathy. Environ Res 60:295-319 (1993).
  65. Callender T, Morrow L, Subramanian K. Evaluation of chronic neurological sequelae after acute pesticide exposure using SPECT brain scans. J Toxicol Environ Health 41:275-284 (1995).
  66. Bocchetta A, Corsini GU. Parkinson's disease and pesticides. Lancet 2:1163 (1986).
  67. Aggazzotti G, Fantuzzi G, Tartoni PL, Predieri G. Chloroform in alveolar air of individuals attending indoor swimming pools. Arch Environ Health 45:175-179 (1990).
  68. Ziem G. Dr. Ziem's Environmental Control Plan. Baltimore, MD:MCS Referal & Resources, 1995.
  69. Roach SA, Rappaport SM. But they are not thresholds: a critical analysis of the documentation of threshold limit values. Am J Ind Med 17:727-753 (1990).
  70. Castleman BI, Ziem GE. Corporate influence on threshold limit values. Am J Ind Med 13:531-559 (1988).
  71. Castleman BI, Ziem GE. Toxic pollutants, science, and corporate influence. Arch Environ Health 44:68,127 (1989).
  72. Ziem GE, Castleman BI. Threshold limit values: historical perspectives and current practice. J Occup Med 31:910-918 (1989).
  73. Castleman BI, Ziem GE. American Conference of Governmental Industrial Hygienists: low threshold of credibility. Am J Ind Med 26:133-143 (1994).
  74. Meggs WJ. Neurogenic inflammation and sensitivity to environmental chemicals. Environ Health Perspect 101(3):234-238 (1993).
  75. Bell I, Miller C, Schwartz G. An olfactory-limbic model of multiple chemical sensitivity syndrome: possible relationships to kindling and affective spectrum disorders. Biol Psychiatry 32:218-242 (1992).
  76. Sorg BA, Hooks MS, Kalivas PW. Neuroanatomy and neurochemical mechanisms of time-dependent sensitization.Toxicol Ind Health 10:369-386 (1994).
  77. Kipen H, Hallman W, Kelly-McNeil K, Fiedler N. Measuring chemical sensitivity prevalence: a questionnaire for population studies. Am J Public Health 85(4):574-577 (1995).
  78. Norback D, Bjornsson E, Janson C, Widstrom J, Boman G. Asthmatic symptoms and volatile organic compounds, formaldehyde, and carbon dioxide in dwellings. J Occup Environ Med 52:338-395 (1995).




Related Articles:


Mold Testing & Sanitizer: